| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 860.65 | 14.8% | 25.6% |
| Total Income | 862.82 | 14.6% | 25.3% |
| Expenditure | 800.34 | 13.8% | 19.4% |
| PBT | 60.11 | 20.8% | 223.5% |
| Net Profit | 41.56 | 21.4% | 237.6% |
| OPM | 11.31% | 0.19pp | 3.50pp |
| NPM | 4.82% | 0.27pp | 3.03pp |
| EPS | 10.12 | 16.9% | 177.3% |
Revenue soars, volumes lag; margins eyed — but price/mix is doing the heavy lifting
Reported profit jumped 238%, but volume growth slowed to just 5.5% and the gains are price-driven, not volume-driven. Management reset guidance lower and pivoted to a multi-year margin expansion story anchored on capex firing next year.
₹41.6 Cr
+237.6% YoY
₹15 Cr
₹12 Cr loss → ₹3 Cr profit; H1 ₹23 Cr loss → ₹6 Cr profit
~20%
PAT excl. JV swing; more modest
5.5%
Q2; guidance reset to 7–8% Q3
On the headline, this quarter looks like a blowout. Revenue ₹860.6 Cr is up 25.6% year-over-year, and net profit ₹41.6 Cr has soared 238%. But dig in, and the story narrows. Of that PAT growth, ₹15 crore swung from a ₹12 crore JV loss in Q2 prior to a ₹3 crore profit now — a one-off swing that masks a weaker organic picture. Strip it out, and earnings growth sits closer to 20%, not 238%. More troubling: the revenue growth is almost entirely price-and-mix, not volume. Volume rose just 5.5%, while price and product mix accounted for roughly 19% of the top-line pop. That's the tension the quarter doesn't resolve.
Where volume stumbled
Management attributed the soft 5.5% volume growth to one-off maintenance disruptions: 20 days of downtime in July, another 15 days in August. On the call, they pointed to Q3 expectations of 7–8% volume growth and framed Q2 as an anomaly. But that reset is telling. In the prior earnings call (Q1 FY27), the guidance tilted toward mid-single-digit volume growth with upside from capex. 5.5% is at the lower end of that band, not an upside case. It comes against a backdrop of a 31.2% industry export decline — Morbi (the ceramic export hub) is 35–45% shut due to geopolitical pressures and freight cost shocks. While Somany's domestic tiles sales grew 25% and exports also grew 25%, the company had to overcome a severely constrained market to show that growth. The question isn't whether Somany can execute; it's whether the export market recovery actually arrives in Q3, as management expects post-Diwali.
What holds up; what doesn't
Revenue up 25%, volume up 5.5%.
Delivered ₹860.6 Cr (+25.6% YoY), volume +5.5% confirmed. Price/mix outpaced volume; internal consistency checks out.
Supported
EBITDA margin 11.7% driven by better utilization and improved JVs.
Delivered OPM 11.3%. EBITDA claim of 11.7% is plausible (EBITDA > OPM). JV swing from ₹12 Cr loss to ₹3 Cr profit confirmed in H1 data (₹23 Cr loss → ₹6 Cr profit).
Supported; JV swing is real but cyclical
GVT (glazed vitrified tiles) mix now 45%, targeting 65–70% by 2028–29 via South plant.
45% current mix stated on call. South Siravit plant expansion is 16M sq m, all-GVT. Expansion timeline Sept 2027. Not contradicted by Q2 numbers.
Supported
Gas price ₹70/SCM, full pass-through achieved; 16–17% price increases April to now.
Q2 revenue +25.6% with volume +5.5% = ~19% price/mix uplift, consistent with gas pass-through + other inflation.
Supported by the data
Morbi exports down 31% industry-wide, but Somany tiles +25%.
Industry export decline -31.2% confirmed. Somany tiles (₹723 Cr segment) up 25%. Market share gain in organized sector.
Supported
Sanitaryware +20%, building solutions +28% in Q2.
Q2 segment growth as stated. Both are high-margin, low-volume products. Expansion capacity online Sept 2027.
Supported but still small % of revenue (16–17% total; target 22–25% in 2–3 yrs)
What changed on this call
EBITDA margin guidance raised: prior call guided 1–1.5% improvement in FY27 over FY26; this call revised to 2–2.5% improvement, now targeting 11.5–12%.
Volume growth reset lower: prior call tilted toward double-digit aspiration; Q2 delivered 5.5%, guidance now 7–8% Q3, single-digit FY27 full year.
JV profitability turned: Q2 prior was ₹12 Cr loss; this Q2 ₹3 Cr profit. H1 swing from ₹23 Cr loss to ₹6 Cr profit.
South capex structure refined: original guidance ₹275 Cr FY27–28 split (65–70% equity). Revised: ₹250 Cr South Siravit, ₹60 Cr Somany side + routine modernization, 50–50 debt-equity split.
Sanitaryware & building solutions emerging: +20% and +28% growth Q2; now 16–17% of revenue, targeted 22–25% by 2028–29.
The bull-bear ledger
Revenue growth real and pricing power evident (16–17% pass-through achieved)
EBITDA margin guidance raised; 11.7% delivered, on track to 12%
Market share gain: Somany tiles +25% despite industry export decline of 31%
South plant capex on track (Sept 2027 firing); GVT ramp mechanism is concrete
JV profitability turnaround; H1 swing from ₹23 Cr loss to ₹6 Cr profit
Sanitaryware +20%, building solutions +28%; high-margin, capacity expanding
Volume growth disappointing (5.5% vs. double-digit prior aspiration)
Revenue growth price-driven (19% mix, 5.5% volume) — sustainability question
JV swing inflates PAT +238%; organic growth closer to 20%
Net profit margin thin (4.8% NPM); interest and tax burden high
Export headwind real (industry -31%); Morbi 35–45% shut; recovery timeline uncertain
South plant delay would push GVT ramp and margin expansion to FY29
Gas price volatility (₹70/SCM) remains; full pass-through may not hold if demand weakens
Ranked risks: what should concern a holder
Geopolitical export headwind; Morbi export hub 35–45% shut (Ukraine war fallout on freight)
MediumIndustry exports down 31.2%. Somany offset with domestic growth and pricing, but global recovery is uncertain. If geopolitical risk persists, export volume may remain pressured into FY28.
Volume growth deceleration; only 5.5% Q2, reset to 7–8% Q3 and single-digit FY27
MediumPrior call hinted at double-digit growth potential. 5.5% Q2 is below expectation. If export market doesn't recover and domestic demand softens, volume may stay in 5–6% range, delaying capex upside.
South plant capex execution; ₹250 Cr target, Sept 2027 production deadline
MediumDelay would push GVT capacity ramp (16M sq m) to FY29, deferring margin expansion from 2–3 years to 3–4 years. The margin guidance 11.5–12% FY27 and 13%+ in 2–3 years hinges on this capex.
JV profitability swing is cyclical; H1 ₹23 Cr loss → ₹6 Cr profit is 7–15% of Somany profit
LowIf utilization or margins decline in JVs, profit could swing back. Not core Somany, but magnitude is material enough to dent earnings if it reverses.
Gas price volatility (current ₹70/SCM, FY26 was ~₹45); pricing power may cap if demand softens
LowFull pass-through achieved Q2, but if global inflation moderates or export demand weakens, pricing power may face headwinds.
How the market is positioned
The stock trades at ₹544.15, off 44% from its all-time high and up 64% from its 52-week low. It sits below the 20-day and 50-day moving averages (₹561 and ₹575) but above the 200-day average (₹489), suggesting a pullback within a longer-term uptrend. RSI sits at 43.8 (neutral). Volume is increasing into the dip — a sign of accumulation.
Institutional ownership is cautious. FII holdings are minimal (1.38%), while DII trimmed their position quarter-over-quarter, dropping from 21.6% in Q4 FY26 to 19.4% in Q1 FY27 — a 221 basis point retreat. Promoters hold steady at 55.2%. The DII exit suggests domestic institutions are stepping back, likely pricing in volume deceleration and waiting for proof of recovery in Q3. That's a warning sign.
The valuation drawdown is significant, but it may be justified. The stock has fallen 44% from peak precisely because the market was pricing in higher volume growth and a faster margin ramp. Q2's 5.5% volume and the reset to single-digit growth for full-year FY27 are disappointments against that backdrop. However, the drawdown also creates an opportunity — if South plant capex fires on time (Sept 2027) and volume accelerates to 7–8% or higher in Q3, the risk-reward tilts favorably.
The debate
What to watch next
1 · Q3 volume growth (target: 7–8%)
Management guided 7–8% volume for Q3, citing end of maintenance disruptions and seasonal demand strength. This is the make-or-break number. If volume misses and lands at 4–5% again, the capex story loses credibility. If it hits 7–8%+, the export recovery narrative holds.
2 · South plant capex progress (Sept 2027 production deadline)
Management stated the facility will fire in production 'exactly same time next year' (Sept 2027). Watch quarterly updates for construction milestones, equipment orders, and hiring ramps. Any delay signals that the margin expansion (11.5–12% to 13%+ by 2029) slips.
3 · GVT mix progression (current 45%, target 65–70% by 2028–29)
GVT (higher-margin product) is key to the margin story. Track quarterly mix data. If GVT can hold or grow faster, it signals pricing power and product acceptance. If mix stalls or slides, margin expansion will be slower than guided.
The single number to track
Organic EBITDA margin, excl. JV swings. The headline is EBITDA 11.7% (guided 11.5–12% for FY27). But strip out the JV swing, and core Somany margin is closer to 11.3% (operating margin). If that can climb to 11.5–12% in Q3–Q4 without JV help, the margin guidance is real. If JV profit is needed to hit target, the story is fragile. That single metric tells you whether the company is executing on operational leverage or relying on one-off items.
Somany delivered a headline-positive quarter: revenue ₹860.6 Cr (+25.6% YoY), OPM 11.3% on track to 12%, and a plausible three-year margin ramp story anchored on South plant and GVT mix shift. But the quarter also revealed a key constraint: volume growth at 5.5% is softer than management's prior double-digit aspiration, and price-mix inflation is doing 74% of the heavy lifting. That's not sustainable.
The reset to single-digit volume guidance (5.5% Q2, 7–8% Q3, single-digit FY27) and the acknowledgment of export headwinds (industry -31%, Morbi 35–45% shut) suggest management is being candid about near-term demand pressures. That's credibility, but it also means the upside is contingent, not assured.
Valuation-wise, the 44% drawdown from ATH and the DII trimming suggest the market has already priced in disappointment. If Q3 volume hits target (7–8%+) and South plant capex stays on track (Sept 2027 production), this stock offers asymmetric upside from current levels. But if either slips, the holding pattern extends, and patience will be tested.
Verdict: Hold. Steady business, real capex catalyst, but volume proof required. Watch Q3.
Revenue soars but volume modest; margin recovery on track via product mix shift
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met revenue guidance (+25.6% vs. +20%+ expected), margin guidance revised up (1-1.5%→2-2.5%), capex on track. Volume miss vs. prior double-digit aspiration (only 5.5%).
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue growth (+25.6%) and margin recovery story (11.5-12% EBITDA guidance, GVT mix shift to 65-70%) are credible and supported by capex execution. However, Q2 volume of only 5.5% and industry export decline (-31%) mean near-term growth is price/mix-driven, not volume-driven. South plant upside is 12-18 months away. Hold pending Q3 volume acceleration.
₹860.6 Cr
Revenue · +25.6% YoY₹41.6 Cr
Reported PAT · +237.6% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue growth 25%, volume 5.5%
METDelivered ₹860.6 Cr (+25.6% YoY), volume +5.5% confirms management claim; price/mix outpaced volume
EBITDA 11.7% due to better utilization and improved JVs
METDelivered OPM 11.3%, EBITDA claim 11.7% is plausible (EBITDA > OPM); JVs swung from ₹12 Cr loss to ₹3 Cr profit in Q2
GVT mix now 45%, targeting 65-70% via South plant
MET45% current mix stated in call; South plant all-GVT expansion (16 million sq m) is credible mechanism. Not contradicted by Q2 numbers.
Gas prices ₹70/SCM, full pass-through achieved, 16-17% price increase April-now
METQ2 revenue +25.6% with only 5.5% volume = ~19% price/mix uplift; consistent with gas pass-through claim
Morbi exports down 31%, but Somany tiles +25%
METIndustry export headwind -31.2%, Somany breakup tiles +25% (₹723 Cr), is internally consistent. Export decline is real headwind despite domestic strength.
Earnings quality
What changed since the last call
EBITDA margin guidance raised
UpgradePrior call: 1-1.5% FY27 margin improvement over FY26. This call: revised to 2-2.5% improvement, with FY27 target 11.5%-12%.
South capex structure refined
NeutralOriginal: ₹275 Cr capex FY27-28, 65-70% equity-funded. Revised: ₹250 Cr South + ₹60 Cr Somany side + routine modernization, 50-50 debt-equity.
Volume growth reset lower
DowngradeQ2 volume only 5.5% (vs. prior 'double-digit' aspiration). Management now guides 7-8% Q3, single-digit FY27. Export headwind (-31% industry) blamed.
JV profitability turned
UpgradeQ2 prior year: ₹12 Cr loss. Q2 this year: ₹3 Cr profit. H1 swing from ₹23 Cr loss to ₹6 Cr profit. Positive inflection.
The Q&A
Analysts probed volume growth disappointment (5.5% in a +25% revenue quarter), Morbi crisis impact, gas pricing floor, and GVT ramp timeline. Management defended single-digit volume as expected, blamed export headwind & maintenance disruptions, addressed gas floor (tiles still cost-competitive), and confirmed South plant Sept 2027 production. No aggressive pushback; management held its guidance confidently.
Pricing sustainability & gas pass-through — Nilesh Sharma, Monomer Capital
PartialGas already down INR2-3 from peak April; further declines unlikely. Price increases are mix of gas + other costs. Full pass-through achieved. Gas currently ₹70/SCM, unlikely to spike further.
GVT mix & capex plans — Sagnik Sarkar, SKP Securities
AnsweredGVT 45% now (up from 41%). Next 16M sq m all GVT; will hit 65-70% in 2-3 years. GVT higher margin but not a standalone lever; benefit is volume absorption + mix shift together.
Capacity utilization & gas pricing floor — Divaneet Savla, Savia Family Office
Answered100% capacity utilization. Even if tiles prices rise 50% from current, still viable vs. alternatives. Gas supply not constrained. No viability threshold identified.
Volume growth trajectory & segment mix — Sneha, Nuvama
Answered5.5% Q2 due to maintenance disruptions (20 days July, 15 days Aug). Expect 7-8% Q3. No double-digit guidance. Sanitaryware +20%, building solutions +28% (both high-margin, expanding capacity Sep 2027).
Medium to long-term margin trajectory — Shruti Mulchandani, Ikigai Asset Management
PartialFY27 guidance 11.5-12% EBITDA. FY28-29 room for improvement. JVs will contribute positively (no margin drag next year). GVT capex accretive. 3-year view: upwards trajectory but not specifying number.
Bathware margins & pricing power — Karan Bhatelia, Asian Markets Securities
AnsweredBathware margins high & stable (couple bits above tiles). Q1 was drag (brass prices shot up); Q2 better. Project 4% hike is volume-based, realized 1.5% via pass-on + pricing. Mix shift to projects (+4%) and adhesive (+40-50% growth) adds 2% EBITDA margin spread over time.
Capacity post-South plant expansion — Bharat Kudikyala, Choice Institutional Equities
AnsweredFY27 sales target 79-80M sq m. FY28 (mid-year South online) adds 10-11M sq m. Total capacity ~90M sq m by end FY28.
Guidance
FY27 'high single digits' growth (post-H1 completion)
MediumH1 growth 25.6% YoY, but export headwind & volume moderation (5.5% Q2) suggest FY27 tapers. Mid-teens growth estimate, not 25%+ sustained.
Sales target FY27: 79-80M sq m; FY28 (with South): 10-11M sq m addition
HighSpecific, operational target. South plant capex on track, Sept 2027 firing (production). Credible.
FY27 EBITDA margins 11.5%-12% (raised from prior 1-1.5% improvement guidance)
HighQ2 achieved 11.7%; trajectory to 12% by year-end is incremental but credible via mix (GVT +4%, JV profit recovery).
FY28-29 margins upwards of 11.5%-12%, with room for improvement
MediumSouth plant adds all-GVT capacity; margin accretive. But specific 13%+ target not given; deferred as multi-year story.
Sanitaryware & building solutions expand 20-28%; push 22-25% of total revenue in 2-3 years (from 16-17% now)
MediumGrowth rates proven in Q2, but high-margin products are low-absolute-volume currently. Margin contribution is real but gradual.
South capex ₹250 Cr (50-50 debt-equity); Somany side ₹60 Cr capex + routine modernization (Sudha ₹15 Cr, Vintage ₹8 Cr)
HighDetailed, on-track. Sept 2027 production deadline for South plant. Revised from original ₹275 Cr guidance but still in neighborhood.
Routine capex ₹70-80 Cr/year (Somany standalone) for debottlenecking & modernization
HighAnnually funded from internal accruals per management statement.
Risks the call surfaced
Geopolitical export headwind
MediumMorbi (export hub) 35-45% shut due to Ukraine war impact on freight & land prices. Industry exports down 31.2%. Recovery timeline uncertain, dependent on geopolitical thaw.
Volume growth deceleration
MediumQ2 volume only 5.5% despite 25.6% revenue growth. Price/mix (+19%) outpaced volume growth. Management resets guidance to 7-8% Q3, single-digit FY27. Risk: volume may remain pressured if demand weakens post-Diwali.
Gas price volatility
LowGas currently ₹70/SCM (up from ₹45 in FY26). Full pass-through achieved in Q2 (+16-17% pricing), but future spikes could hit margins if pricing power caps. War escalation risk remains.
South plant capex execution
Medium₹250 Cr South capex for 16M sq m GVT expansion, targeted Sept 2027 production. Delay would push capacity ramp & GVT mix upside to FY29, delaying margin expansion & volume scale.
JV profitability sustainability
LowQ2 prior: ₹12 Cr loss. Q2 current: ₹3 Cr profit. This swing inflates PAT growth (+237.6% YoY). Risk: if JV margins revert to loss, PAT would be heavily impacted. Exposure: ~₹3-6 Cr H1 swing is ~7-15% of Somany consolidated profit.
Management
Score 8/10. Clear & transparent on headwinds (Morbi export crisis, gas volatility, volume moderation). Detailed on capex plans (₹250 Cr South, Sept 2027 firing). Addresses analyst probes directly (capacity, pricing, GVT mix). No evasion detected. Acknowledges constraints (war, freight rates, volume cap at 5.5% this quarter) candidly. Revenue guidance met (+25.6% YoY vs. +20%+ expected). Margin guidance revised up (1-1.5% → 2-2.5%), now tracking 11.5-12% EBITDA for FY27. Capex on track (South plant Sept 2027 deadline credible). Volume guidance reset lower (double-digit aspiration → 5.5% Q2, 7-8% Q3) but execution honest.
1 · Q3 FY27 (Dec 2026)
Volume acceleration to 7-8%; export recovery post-Diwali/geopolitical relief
2 · Sept 2027 (FY28)
South plant ramp (16M sq m GVT capacity), GVT mix jump 45%→50%+
3 · FY28-29
GVT mix 65-70% achieved; margin target 12%+ via mix + capacity absorption
Hold pending Q3 volume acceleration.